Can You Still Ride This Month's 3 Biggest Winners To Greater Gains?

Biotech dominates in January as Intercept, Cell Therapeutics, and Neurocrine all surge after good drug-trial news.

Jan 27, 2014 at 12:15PM

One of the best things about being a long-term investor is that the law of gravity need not apply to good stocks -- what goes up doesn't necessarily have to come down. But some stocks can still fly too close to the sun, singing investors who bought in at too dear a price. When we're talking about momentum stocks, one investor's long-term winner could be another's warning sign, so it's important to separate the hype from the truth to find out just why a stock is soaring today, and whether it can keep rising tomorrow.

Today we'll look at three of the best-performing stocks on the market over the past month of trading. They might still be great candidates for your portfolio, but we won't know until we dig a little deeper.


Monthly Performance

Market Cap

P/E Ratio

Intercept Pharmaceuticals  (NASDAQ:ICPT)


$5.71 billion


Cell Therapeutics  (NASDAQ:CTIC)


$444 million


Neurocrine Biosciences (NASDAQ:NBIX)


$1.22 billion


Source: Finviz, YCharts , and Yahoo! Finance .

Intercept Pharmaceuticals
Few public companies in any industry -- even in the incredibly volatile biotech space -- have ever enjoyed the rocket ride Intercept went on earlier this month -- in just one day, shares gained more than 300% after Intercept publicized a positive recommendation for its obeticholic acid, or OCA, treatment for nonalcoholic steatohepatitis, or NASH. The treatment showed statistically significant improvements in the condition of many patients in Intercept's phase 2b trial. Considering the sheer size of the affected population -- up to 12% of Americans have NASH -- many investors felt this report marked the beginning of a major blockbuster drug, one that has no visible competition. The megapop continued for a second day and Intercept's shares topped out at a two-day gain of more than 500%.

ICPT Total Return Price Chart

ICPT Total Return Price data by YCharts.

Since topping out at about $445, Intercept's shares sank back to a slightly more reasonable price of about $300 (as of this writing), and the 500% gain became a 350% gain. Still, investors who have held on since Intercept's late-2012 IPO have nothing to complain about, as they have a 15-bagger on their hands after little more than one year of trading.

However, Intercept is still small enough and tightly focused enough that its share-price moves in the near future will likely be driven entirely by rumors, press releases, and short-selling raids. That adds up to extreme volatility, and months or years can be expected to pass before the Food and Drug Administration clears OCA -- if it is cleared at all. Iron-willed investors may be able to clamp down and hold on for the ride, but those with a weaker understanding of biotech investing, or a weaker constitution when it comes to volatility, are probably better off on the sidelines.

Cell Theraputics
Unlike its larger biotech peer at the top of this week's list, Cell Therapeutics hasn't been propelled by one single massive pop. As is often the case, the company has been rising throughout January as a result of several pieces of good news. Cell Therapeutics' Pixuvri, a treatment for non-Hodgkin lymphoma, was approved by Britain's National Institute for Health and Care Excellence as a cost-effective treatment option. On the other side of the pond, Cell Therapeutics' leukemia drug Tosedostat was released from a partial FDA clinical hold.

Later in the month, Cell Therapeutics provided guidance for the rest of 2014 that indicated further progress on trials for pacritinib and Opaxio, which gave shares another double-digit boost. The company also managed to regain the full rights to both Pixuvri and Opaxio from former partner Novartis (NYSE:NVS). All told, the positive momentum propelled Cell Therapeutics to a double for the month of January:

CTIC Total Return Price Chart

CTIC Total Return Price data by YCharts.

However, Fool contributor and biotech specialist Sean Williams pointed out that this recent good news is simply one bump on a steady downward slide that has shredded virtually all shareholder value over the past decade. Indeed, when examined on a 10-year timeline, we find that Cell Therapeutics' recent pop is completely invisible to the naked eye:

CTIC Total Return Price Chart

CTIC Total Return Price data by YCharts.

It's only when we zoom in to the past year that Cell Therapeutics again looks like a good investment. Williams, though, also notes that the company didn't actually wrest back the rights to two of its biggest drugs -- Novartis simply didn't want to license the drugs in the first place. The company has only one drug approved, and even then only in Europe. On the other hand, analysts at Roth Capital recently pegged their price target for Cell Therapeutics shares at $7, up from $6, and at current share prices this represents a hefty 75% upside. History isn't on Cell Therapeutics' side, so it may be better to sit on the sidelines here.

Neurocrine Biosciences
The biotech clean sweep is complete for the month of January with Neurocrine Biosciences, another developmental-stage company with one huge day propelling it higher. Neurocrine has taken investors on quite the violent ride over the last few months, and all over the same drug -- its tardive dyskinesia drug NBI-98854 produced disappointing results last September, but after reworking the study Neurocrine managed to produce some success. Investors then flocked to the stock, which nearly doubled in a single day:

NBIX Total Return Price Chart

NBIX Total Return Price data by YCharts.

Neurocrine's megapop has proven to be more sustainable than top performer Intercept's leap, as it remains roughly in line with its post-pop closing price several weeks later. However, while both Neurocrine and Intercept have developed promising new drugs with no apparent competition, investor enthusiasm over Intercept's positive progress was so extreme that it makes Neurocrine look like a bargain by comparison. It might be a long way from FDA approval, but Sean Williams thinks that NBI-98854 has a better chance of surprising investors to the upside with its long-term sales figures. This month's megapops are not for the faint of heart, but if you still want to rush in after the big gain, Neurocrine might be your best bet.

Still looking for a great long-term biotech investment? Look here
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers